CEACAM5 and breast carcinoma: As a result, the American Society of Clinical Oncology (ASCO) guidelines do not currently recommend the use of serum CA 15–3 and CEA for or screening, diagnosis, staging, or routine surveillance of breast cancer patients after primary therapy[13, 14].